Myriad Genetics (MYGN) Liabilities and Shareholders Equity (2010 - 2026)

Myriad Genetics (MYGN) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $673.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 33.04% year-over-year to $673.7 million; the TTM figure through Mar 2026 stood at $2.8 billion (down 33.68% YoY), while the FY2025 annual figure was $706.6 million, down 31.24% from the prior year.
• Liabilities and Shareholders Equity eased to $673.7 million in Q1 2026 per MYGN's latest filing, from $706.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.3 billion in Q1 2022 and bottomed at $673.7 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $1.0 billion across 5 years, with a median of $1.1 billion in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity declined 1.9% — and 2025, when it plunged 37.58%.
• Myriad Genetics' Liabilities and Shareholders Equity stood at $1.2 billion in 2022, then decreased by 4.35% to $1.1 billion in 2023, then fell by 10.37% to $1.0 billion in 2024, then slumped by 31.24% to $706.6 million in 2025, then dropped by 4.66% to $673.7 million in 2026.
• Business Quant data shows MYGN's Liabilities and Shareholders Equity at $673.7 million in Q1 2026, $706.6 million in Q4 2025, and $728.1 million in Q3 2025.